Loading...
XHKG
9960
Market cap156mUSD
Dec 05, Last price  
1.22HKD
1D
-0.81%
1Q
-18.12%
IPO
-85.12%
Name

Kindstar Globalgene Technology Inc

Chart & Performance

D1W1MN
XHKG:9960 chart
P/E
P/S
1.19
EPS
Div Yield, %
2.33%
Shrs. gr., 5y
0.88%
Rev. gr., 5y
2.18%
Revenues
928m
-4.10%
706,202,000832,791,000891,391,000930,673,0001,386,591,000967,260,000927,568,000
Net income
-55m
L
-52,674,000-169,582,000-970,120,000-1,454,234,00075,457,00041,286,000-54,588,000
CFO
-44m
L+198.50%
53,895,00099,448,00073,462,00068,028,00021,407,000-14,780,000-44,119,000
Dividend
Jun 09, 20250.0238 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
IPO date
Jul 16, 2021
Employees
3,214
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT